Get the Stockscreener App
1.55
4.03%
0.06
Dogwood Therapeutics Inc stock is traded at $1.55, with a volume of 70,814.
It is up +4.03% in the last 24 hours and down -8.82% over the past month.
Dogwood Therapeutics Inc is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. The pipeline is focused on treating chronic neuropathic pain and neuropathy. The Company operates in one segment and is a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and peripheral neuropathy associated with cancer.
See More
Previous Close:
$1.49
Open:
$1.49
24h Volume:
70,814
Relative Volume:
0.74
Market Cap:
$52.13M
Revenue:
-
Net Income/Loss:
$-28.32M
P/E Ratio:
-0.1462
EPS:
-10.6039
Net Cash Flow:
$-15.52M
1W Performance:
-1.27%
1M Performance:
-8.82%
6M Performance:
-74.59%
1Y Performance:
-67.71%
1-Day Range:
$1.42
$1.56
1-Week Range:
$1.42
$1.6699
52-Week Range:
$1.28
$9.50
Dogwood Therapeutics Inc Stock (DWTX) Company Profile
Name
Dogwood Therapeutics Inc
Sector
Industry
Phone
(866) 620-8655
Address
44 MILTON AVENUE, ALPHARETTA
Compare DWTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DWTX
Dogwood Therapeutics Inc
|
1.55 | 52.13M | 0 | -28.32M | -15.52M | -10.60 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dogwood Therapeutics Inc Stock (DWTX) Latest News
Dogwood Therapeutics Inc (DWTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dogwood Therapeutics shareholders approve board proposals at annual meeting By Investing.com - Investing.com South Africa
Dogwood Therapeutics Shareholders Approve Key Governance Measures - TipRanks
Dogwood Therapeutics (DWTX) investors approve share increase and annual Say-on-Pay - Stock Titan
[Form 4] Dogwood Therapeutics, Inc. Insider Trading Activity - Stock Titan
Dogwood Therapeutics (DWTX) director awarded 16,800 options at $1.50 strike price - Stock Titan
Dogwood Therapeutics Inc (DWTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Dogwood Therapeutics Inc (DWTX) Institutional Confidence - TradingKey
Dogwood Therapeutics Inc (DWTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dogwood Therapeutics Inc (DWTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Dogwood Therapeutics Inc (DWTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Dogwood Therapeutics Inc (DWTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Dogwood Therapeutics Inc. (DWTX) Q1 2026 Earnings: Narrower-than-Expected Loss Lifts SharesAnnual Financial Report - newsline.com
Dogwood Therapeutics Inc. (DWTX) Q1 2026 Earnings: Narrower-than-Expected Loss Signals Cost Discipline - newsline.com
DWTX Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesFinal Results - newsline.com
DWTX Q1 2026 Earnings: Narrower-than-expected loss as stock slides 8.5%EBITDA Analysis - newsline.com
DWTX Q1 2026 Earnings: Narrower Loss Meets Investor Skepticism as Stock DeclinesUpward Estimate Revision - newsline.com
DWTX News | DOGWOOD THERAPEUTICS INC (NASDAQ:DWTX) - ChartMill
Dogwood Therapeutics Inc. (DWTX) Q1 2026 Earnings: Better-Than-Expected Loss Highlights Cost Discipline - newsline.com
Dogwood Therapeutics Inc. (DWTX) Rises 1.2% as Stock Holds Above Key SupportVolume Climax - newsline.com
Dogwood Therapeutics Inches Lower as Stock Tests Key Support Near $1.69Take Profit Levels - Newser
Dogwood Therapeutics Inc. (DWTX) Q1 2026 Earnings: Narrower Loss Surprises as Pre‑Revenue Biotech Focuses on Pipeline ProgressEarnings Whisper Number - newsline.com
Dogwood Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Continued Preclinical DevelopmentEPS Growth Rate - Newser
Analysts Are Bullish on Top Healthcare Stocks: Invivyd (IVVD), Century Therapeutics (IPSC) - The Globe and Mail
PRODU - produ
DWTX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $12.00 - GuruFocus
H.C. Wainwright Maintains Dogwood Therapeutics(DWTX.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Dogwood launches 12-week extension study for pain drug Halneuron - Investing.com UK
Dogwood launches 12-week extension study for pain drug Halneuron By Investing.com - Investing.com Australia
Dogwood Therapeutics Announces Commencement of Halneuron® - GlobeNewswire
Dogwood Therapeutics, Inc. Q1 2026 SEC 10-Q Filing – Financial Statements, Management Discussion, and Risk Factors – Minichart - minichart.com.sg
Dogwood Therapeutics 1Q Rev $0.00 >DWTX - Moomoo
Armistice Capital (NASDAQ: DWTX) reports 9.99% Dogwood stake - Stock Titan
Dogwood Therapeutics 1Q 2026: Revenue $2.41M, EPS ($0.15) — 10-Q Summary - TradingView
Dogwood Therapeutics (Nasdaq: DWTX) posts Q1 2026 loss, flags cash risk - Stock Titan
Dogwood Therapeutics Announces First Quarter 2026 Financial Results - Sahm
Dogwood Therapeutics 1Q Loss $4.99M >DWTX - Moomoo
Dogwood Therapeutics Reports First Quarter 2026 Results and Progress on Pain Pipeline - citybuzz -
Dogwood Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Dogwood Therapeutics Reports Q1 2026 Results, Advances Halneuron® and SP16, and Secures $100M Antiviral Partnership 1 - Minichart
Dogwood Therapeutics (NASDAQ:DWTX) Beats EPS Estimates in Q1 2026, Phase 2b Trial on Track - ChartMill
DOGWOOD THERAPEUTICS ($DWTX) Releases Q1 2026 Earnings - Quiver Quantitative
Dogwood Therapeutics reports Q1 2026 net loss $5.0M, cash $13.2M, Halneuron Phase 2b on track - TradingView
Dogwood Therapeutics (DWTX) narrows Q1 loss and advances pain pipeline - Stock Titan
Dogwood Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Dogwood Therapeutics Q1 net loss narrows, no revenue reported - TradingView
DWTX: Pipeline advances, reduced net loss, and new partnership drive positive outlook for 2026 - TradingView
Chemo pain drug developer Dogwood lands FDA, NCI backing and $100M deal - Stock Titan
Dogwood Therapeutics : Corporate Presentation (Dogwood Therapeutics Non Confidential Corporate Update May 2026) - marketscreener.com
Dogwood Therapeutics Inc expected to post a loss of 26 cents a shareEarnings Preview - TradingView
TradingKey - TradingKey
Dogwood Therapeutics Inc Stock (DWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):